{"id":769,"date":"2021-01-14T12:13:53","date_gmt":"2021-01-14T12:13:53","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=769"},"modified":"2021-01-14T12:13:53","modified_gmt":"2021-01-14T12:13:53","slug":"08-jan-2021-interferon-beta-associated-with-decrease-in-death-risks","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/08-jan-2021-interferon-beta-associated-with-decrease-in-death-risks\/","title":{"rendered":"(08 Jan 2021) Interferon beta- associated with decrease in death risks"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.intimp.2020.107329<\/p>\n<p class=\"\">We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units of IFN-beta1-a and Lopinavir 400 mg and Ritonavir 100 mg every 12 h (case group) for 14 days besides standard care and age- and sex- matched COVID-19 patients with receiving lopinavir\/ritonavir (control group) at Masih Daneshvari Hospital as a designated hospital for COVID-19 between Feb 19 and Apr 30, 2020. Multivariate analysis was done to determine the impact of IFN-beta1-a on outcome and all-cause mortality. 152 cases in IFN-beta1-a group and 304 cases as control group were included. IFN-beta1-a group stayed at hospital longer and required noninvasive ventilation more than control group (13 vs. 6 days, p = 0.001) and (34% vs. 24%, p = 0.04), respectively. During treatment, 57 (12.5%) patients died. The death rate in case and control groups was 11% and 13% respectively. In multivariate analysis, not receiving IFN-beta1-a (HR 5.12, 95% CI: 2.77-9.45), comorbidity (HR 2.28, 95% CI: 1.13-4.60) and noninvasive ventilation (HR 2.77, 95% CI: 1.56-4.93) remained significantly associated with all-cause mortality. In this study, risk of death decreased by using IFN-beta1-a in COVID-19 patients.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients https:\/\/doi.org\/10.1016\/j.intimp.2020.107329 We conducted a retrospective study of all adult confirmed COVID-19 hospitalized patients who received combination of three doses of 12 million international units&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/08-jan-2021-interferon-beta-associated-with-decrease-in-death-risks\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(08 Jan 2021) Interferon beta- associated with decrease in death risks&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,30,12],"tags":[63,41],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/769"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=769"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/769\/revisions"}],"predecessor-version":[{"id":770,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/769\/revisions\/770"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}